Bioequivalence Study of Fixed Dose Combination of Bempedoic Acid, Ezetimibe, and Rosuvastatin in Healthy Subjects

The primary objective of this study is to evaluate the **bioequivalence** of a fixed-dose combination of Bempedoic Acid/Ezetimibe and Rosuvastatin compared to their individual tablet forms. This assessment is clinically relevant as it determines whether the combination formulation provides the same therapeutic effect and safety profile as the separate administration of these medications, which are used to manage cholesterol levels. No secondary objectives are specified for this study.

The clinical trial involves a study population that includes both **male** and **female** participants. The age range of the participants is categorized as **adults**, although specific age limits are not provided. The trial population is noted to include a **vulnerable population**, but further details on the nature of this vulnerability are not specified. The sponsor has not provided information regarding the total number of participants involved in the study. Participants do not have any specific medical conditions as a prerequisite for inclusion in the trial. Lifestyle considerations such as diet, physical activity, or habits are not detailed in the available data. The selection criteria for the trial population, including any key inclusion or exclusion criteria, have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the **bioequivalence** of a fixed-dose combination of Bempedoic Acid, Ezetimibe, and Rosuvastatin compared to their individual tablet forms. This study is a Phase 2 trial, which is categorized as a randomized, double-blind, controlled trial. The estimated recruitment start date is September 8, 2025, with an anticipated end date of December 2, 2025. The trial does not target any specific medical condition, as indicated by the absence of a defined medical condition in the protocol.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be randomized into treatment groups. The trial will include multiple follow-up visits to monitor the participants' response to the treatment and to ensure adherence to the study protocol. These visits will also serve to collect data on any adverse events or side effects experienced by the participants. The end-of-study visit will conclude the trial, during which final assessments will be conducted to evaluate the primary and secondary endpoints of the study.

The expected length of participant involvement in the trial is approximately three months, from the initial screening to the end-of-study visit. Participants may be subject to early termination from the study if they experience significant adverse effects, fail to comply with the study protocol, or withdraw consent. The trial is conducted under strict ethical guidelines to ensure the safety and well-being of all participants throughout the study duration.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 2 study, which typically focuses on assessing the efficacy of a treatment in a specific patient population. The trial is scheduled to commence recruitment on September 8, 2025, with an estimated completion date of December 2, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 2 trials generally involve the use of validated scales, laboratory tests, or patient-reported outcomes to measure treatment effects. The data collection and analysis will be conducted according to the standard protocols for Phase 2 trials, ensuring rigorous assessment of the treatment's impact on the targeted medical condition. The trial will adhere to established methodologies to ensure the reliability and validity of the efficacy assessments.